<DOC>
	<DOCNO>NCT03071094</DOCNO>
	<brief_summary>This study Evaluate Safety Efficacy Combination Oncolytic Immunotherapy Pexa-Vec With PD-1 Receptor Blocking Antibody Nivolumab First-line Treatment Advanced Hepatocellular Carcinoma ( HCC ) .</brief_summary>
	<brief_title>A Trial Evaluate Safety Efficacy Combination Oncolytic Immunotherapy Pexa-Vec With PD-1 Receptor Blocking Antibody Nivolumab First-line Treatment Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antibodies , Blocking</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Histological/cytological diagnosis primary HCC , exclude cholangiocarcinoma , hepatocholangiocarcinoma , fibrolamellar carcinoma hepatoblastoma Advanced stage HCC per EASLEORTC ( European Association Study LiverEuropean Organisation Research Treatment Cancer ) guideline , i.e . patient candidate curative intervention candidate locoregional modality Patients naïve systemic therapy HCC Tumor status ( determine radiology evaluation ) : At least one measurable viable tumor liver , ≥1 cm long diameter ( LD ) , use dynamic imaging technique ( arterial phase triphasic computerized tomography [ CT ] scan , dynamic contrastenhanced magnetic resonance image [ MRI ] ) , injectable imagingguidance ( CT ultrasound ) At least one tumor receive prior localregional treatment , exhibit definitive growth viable tumor since prior localregional treatment HCC undertake least 4 week prior enrolment 3 month prior enrolment radioembolization ChildPugh Class A . Note : paracentesis , albumin infusion diuretic treatment use downgrade ChildPugh score ( e.g. , improve severe moderate/mild moderate mild ascites ) Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Adequate hematological , hepatic , renal function Additional inclusion criterion exist Histological diagnosis cholangiocarcinoma , hepatocholangiocarcinoma , fibrolamellar carcinoma hepatoblastoma Symptomatic cardiovascular disease , include limited significant coronary artery disease ( e.g. , require angioplasty stenting ) congestive heart failure within precede 12 month Current past history cardiovascular disease ( e.g. , past history myocardial infarction , ischemic cardiomyopathy ) unless cardiology consultation clearance obtain study participation History moderate severe ascites , bleed esophageal varix , hepatic encephalopathy pleural effusion relate liver insufficiency within 6 month screen ; patient adequately treat esophageal varix allow Active , know suspect significant immunodeficiency due underlie illness include HIV/AIDS , autoimmune disease , and/or immunesuppressive medication include highdose corticosteroid History severe eczema and/or ongoing severe inflammatory skin condition ( determined Investigator ) require medical treatment Any known allergy reaction component nivolumab formulation excipients Additional exclusion criterion exist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>